Polymun Scientific

Carbamylated Epo-Fc Fusion Protein

Polymun has developed a fusion protein consisting of the Fc domain and hinge region of human IgG1 and of two recombinant human EPO molecules. Carbamylation of EPO-FC fusion protein (cEPO-FC) retains the tissue protective action but prevents hematopoietic actions. This allows continuous therapy concepts without risk of thrombosis.Fusions protein containing the constant region of IgG show prolonged half-lives compared with the parent protein and Fc regions allow receptor mediated uptake through the lungs which enables dosing by inhalation.

CEPO-FC was investigated in several animal models showing tissue- and neuroprotective effects. Impressive results were obtained for the treatment of Parkinson’s disease using the most accepted 6-OHDA rat model. In this model CEPO-FC conferred neuroprotective and neurorescue benefits without the side effects associated with polycythemia (Tayra et al. 2013).Tissue and neuroprotection was also demonstrated in models of ischemia/reperfusion (Simon et al. 2011) and spinal cord injury (unpublished data).

PATENTS

Erythropoietin fusion proteingranted by: AU 2008217202; CA 2,678,986; CN 200880005733.7; EA 017377; EP 1 961 821; IN 295813; KR 10-1539120; US 9,085,640

PUBLICATIONS

Hooshmandi E, Motamedi F, Moosavi M, Katinger H, Zakeri Z, Zaringhalam J, Maghsoudi A, Ghasemi R, Maghsoudi N (2018) CEPO-Fc (An EPO Derivative) Protects Hippocampus Against Aβ-induced Memory Deterioration: A Behavioral and Molecular Study in a Rat Model of Aβ Toxicity. Neuroscience 388:405-417